As we stand at the forefront of major changes across the healthcare industry, a pathway for the approval of generic biologics will be one of the major initiatives in the government’s efforts to achieve reduced costs.
Sartorius Stedim Biotech partners with SAFC Biosciences to integrate filtration and liquid handling systems with cell culture media manufacturing services.
While the suggestion that the United States government bail out venture capital firms has failed to attract support from government leaders—and would surely raise taxpayer ire—the mood is quite different overseas, according to recent media reports.
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee voted last month in favor of a proposal by Sens. Kay Hagan (D-N.C.), Michael Enzi (R-WY) and Orrin Hatch (R-UT) to create a follow-on biologics (FOB) pathway that provides 12 years of data exclusivity for brand-name biologic drugs.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.